AR118898A1 - Dominios variantes para multimerizar proteínas y su separación - Google Patents
Dominios variantes para multimerizar proteínas y su separaciónInfo
- Publication number
- AR118898A1 AR118898A1 ARP200101330A ARP200101330A AR118898A1 AR 118898 A1 AR118898 A1 AR 118898A1 AR P200101330 A ARP200101330 A AR P200101330A AR P200101330 A ARP200101330 A AR P200101330A AR 118898 A1 AR118898 A1 AR 118898A1
- Authority
- AR
- Argentina
- Prior art keywords
- proteins
- immunoglobulin
- separation
- variant domains
- multimerizing
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000000926 separation method Methods 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 6
- 102000018358 immunoglobulin Human genes 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere a medios y métodos para producir y aislar proteínas inmunoglobulinas que comprenden un primer y un segundo polipéptido de inmunoglobulina, en particular medios y métodos para producir y separar proteínas que comprenden un primer y un segundo polipéptido de inmunoglobulina. Mediante la inclusión de variaciones en los aminoácidos, y dominios de separación variantes de una célula que produce la proteína inmunoglobulina deseada, se puede separar de las mezclas de proteínas inmunoglobulinas una proteína inmunoglobulina deseada tal como se produjo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19173633 | 2019-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118898A1 true AR118898A1 (es) | 2021-11-10 |
Family
ID=66476558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200101330A AR118898A1 (es) | 2019-05-09 | 2020-05-08 | Dominios variantes para multimerizar proteínas y su separación |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210054049A1 (es) |
EP (1) | EP3966238A2 (es) |
JP (1) | JP2022534674A (es) |
KR (1) | KR20220017909A (es) |
CN (2) | CN114702587A (es) |
AR (1) | AR118898A1 (es) |
AU (1) | AU2020268684A1 (es) |
BR (1) | BR112021022405A2 (es) |
CA (1) | CA3139402A1 (es) |
IL (1) | IL287928A (es) |
MA (1) | MA55884A (es) |
MX (1) | MX2021013646A (es) |
SG (1) | SG11202112399PA (es) |
TW (1) | TW202108613A (es) |
WO (1) | WO2020226502A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020019795A2 (pt) * | 2018-03-30 | 2021-01-05 | Merus N.V. | Anticorpo multivalente |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
US7135287B1 (en) * | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US6680209B1 (en) * | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
WO2005092925A2 (en) * | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
CN105177091A (zh) * | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | 用于纯化双特异性抗体的抗体修饰方法 |
DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
EP4368721A2 (en) * | 2007-09-26 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
SG10201914027VA (en) | 2008-06-27 | 2020-03-30 | Merus Nv | Antibody producing non-human mammals |
CA2755640C (en) | 2009-03-20 | 2018-05-22 | Genentech, Inc. | Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr |
JP6310394B2 (ja) * | 2011-10-10 | 2018-04-11 | ゼンコア インコーポレイテッド | 抗体を精製する方法 |
AU2013249985B2 (en) * | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
ES2743216T3 (es) * | 2013-03-15 | 2020-02-18 | Xencor Inc | Proteínas heterodiméricas |
JP6771385B2 (ja) | 2014-02-28 | 2020-10-21 | メルス ナムローゼ フェンノートシャップ | 二重特異性抗体および医薬組成物 |
WO2016016299A1 (en) * | 2014-07-29 | 2016-02-04 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
MA41375A (fr) * | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
RU2021136863A (ru) * | 2016-06-10 | 2022-02-01 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Конъюгированные с лизином иммуноглобулины |
EA202090005A1 (ru) | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Антитела, модулирующие биологическую активность, проявляемую клеткой |
TW201920657A (zh) | 2017-07-06 | 2019-06-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
TW201920264A (zh) | 2017-07-06 | 2019-06-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的結合分子 |
AU2018312816B2 (en) | 2017-08-09 | 2021-05-27 | Merus N.V. | Antibodies that bind EGFR and cMET |
BR112020019795A2 (pt) | 2018-03-30 | 2021-01-05 | Merus N.V. | Anticorpo multivalente |
-
2020
- 2020-05-08 CN CN202210393772.0A patent/CN114702587A/zh active Pending
- 2020-05-08 SG SG11202112399PA patent/SG11202112399PA/en unknown
- 2020-05-08 BR BR112021022405A patent/BR112021022405A2/pt unknown
- 2020-05-08 TW TW109115418A patent/TW202108613A/zh unknown
- 2020-05-08 AU AU2020268684A patent/AU2020268684A1/en active Pending
- 2020-05-08 AR ARP200101330A patent/AR118898A1/es unknown
- 2020-05-08 MX MX2021013646A patent/MX2021013646A/es unknown
- 2020-05-08 WO PCT/NL2020/050298 patent/WO2020226502A2/en unknown
- 2020-05-08 EP EP20727737.7A patent/EP3966238A2/en active Pending
- 2020-05-08 MA MA055884A patent/MA55884A/fr unknown
- 2020-05-08 JP JP2021566278A patent/JP2022534674A/ja active Pending
- 2020-05-08 CA CA3139402A patent/CA3139402A1/en active Pending
- 2020-05-08 US US16/870,715 patent/US20210054049A1/en active Pending
- 2020-05-08 KR KR1020217039330A patent/KR20220017909A/ko unknown
- 2020-05-08 CN CN202080048983.XA patent/CN114430745A/zh active Pending
-
2021
- 2021-11-08 IL IL287928A patent/IL287928A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210054049A1 (en) | 2021-02-25 |
MX2021013646A (es) | 2022-01-31 |
BR112021022405A2 (pt) | 2022-04-19 |
CA3139402A1 (en) | 2020-11-12 |
CN114430745A (zh) | 2022-05-03 |
WO2020226502A9 (en) | 2022-03-03 |
CN114702587A (zh) | 2022-07-05 |
JP2022534674A (ja) | 2022-08-03 |
WO2020226502A2 (en) | 2020-11-12 |
AU2020268684A1 (en) | 2021-12-09 |
TW202108613A (zh) | 2021-03-01 |
IL287928A (en) | 2022-01-01 |
KR20220017909A (ko) | 2022-02-14 |
WO2020226502A3 (en) | 2021-02-04 |
MA55884A (fr) | 2022-03-16 |
SG11202112399PA (en) | 2021-12-30 |
EP3966238A2 (en) | 2022-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR120511A2 (es) | Producción de proteínas heteromultiméricas | |
HRP20191446T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
MX2019002252A (es) | Metodo para producir una proteina de fusion de anticuerpo. | |
ECSP077282A (es) | Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos | |
BR112012025326A2 (pt) | "extração seletiva de proteínas de algas de água salgada" | |
UY37970A (es) | Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus | |
AR094375A1 (es) | Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular | |
EA201070987A1 (ru) | Очищенные гибридные белки иммуноглобулина и способы их очищения | |
MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
WO2014146074A3 (en) | Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens | |
MX2018009331A (es) | Metodos para extraer proteinas a partir de un material a base de sangre. | |
AR115695A1 (es) | Moléculas proteicas multifuncionales que comprenden decorina y uso de estas | |
BR112015021785A2 (pt) | Promotores de levedura para expressão de proteína | |
CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
ECSP20075234A (es) | Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos | |
AR118898A1 (es) | Dominios variantes para multimerizar proteínas y su separación | |
CO2023003453A2 (es) | Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados | |
WO2018120843A9 (zh) | 一种三功能分子及其应用 | |
PE20190966A1 (es) | Factor viii direccionado a los globulos rojos y metodo para su uso | |
JP2017524366A5 (es) | ||
MX2018015596A (es) | Proteina de fusion entre el factor de viabilidad de los conos derivado de bastones de forma corta y un peptido hidrofilo. | |
AR107900A1 (es) | Un gen de síntesis de tentoxina, un método para producir tentoxina o dihidrotentoxina usando el gen, y un transformante que lo comprende | |
BR112018005464A2 (pt) | expressão de proteínas contendo fc | |
MY186776A (en) | Method for producing lipid |